Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Roswell Park Cancer Institute
DescriptionCancer vaccine comprising SVN53-67/M57-KLH, a peptide mimic targeting survivin (BIRC5), in adjuvant Montanide ISA 51
Molecular Target Survivin (BIRC5)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today